Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma

@article{Lin2010FiveYearFO,
  title={Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma},
  author={Yi Lin and Morie A. Gertz and Sumithra J. Mandrekar and Kristina M Laumann and Angela Dispenzieri and Suzanne R. Hayman and Francis K. Buadi and David Dingli and Douglas J. Padley and Dennis A Gastineau and Shaji K. Kumar and Vincent S. Rajkumar and Martha Q. Lacy},
  journal={Blood},
  year={2010},
  volume={116},
  pages={1958-1958}
}
Abstract 1958 Vaccines may offer additional benefit as consolidation therapy after plateau phase or autologous stem cell transplant (ASCT) for multiple myeloma (MM). We have reported previously the results of another phase II trial showing that using APC8020 (Mylovenge™) after ASCT improved the overall survival (OS 5.3 yrs, 95% CI 4.0 yrs – NA) compared to ASCT alone (3.4 yrs, 95% CI 2.7 – 4.6 yrs; p = 0.02; Lacy, AJH (84): 799). We now report the results from a randomized, phase II trial using…